Searched for
GMP ANALYSIS
Sai Parenteral’s IPO: Issue subscribed just 4% on day 1. Check price band, GMPSai Parenteral’s IPO opened with weak demand, subscribing just 4% on day one amid no grey market premium. While retail and NII interest rem...- 'Drug companies in upgrade mode need more time for GMP compliance': IDMAA pharma group is requesting more time for manufacturers to meet new quality standards. Many companies have started upgrades but face genui...
- ICICI Pru AMC IPO: 7.4% GMP signals strong investor appetite as issue opens for bidding todayICICI Pru AMC’s IPO opened to strong sentiment, with a steady GMP of Rs 160–165 indicating a potential 7.4% listing gain. The robust premiu...
- Wakefit IPO sees slow subscription on Day 2 so far; GMP falls. Should you apply?Wakefit Innovations’ ₹1,288.89 crore IPO saw modest traction on day two, with 34% subscription against 3.63 crore shares on offer. Retail i...
- Small pharma firms may face closure as regulator tightens quality checksMany small drug makers face closure as regulators inspect facilities for quality standards. Thousands of plants may shut down if upgrades a...
- Cough syrup deaths: Probe against Coldrif manufacturer exposed lapses by TNFDALapses by the Tamil Nadu Food and Drug Administration in enforcing basic regulatory norms have been exposed following the deaths of childre...
- Forget GMP! How this Rs 900 crore Edelweiss IPO fund picks winning stocks before listingEdelweiss Recently Listed IPO Fund, a Rs 900 crore scheme, offers systematic exposure to high-growth IPOs beyond benchmarks. The fund consi...
- Cough syrup deaths: Ensure drug manufacturers comply with Revised Schedule M norms, govt to statesThe Union health ministry addressed cough syrup quality. A meeting reviewed drug norm compliance. This followed child deaths linked to syru...
- Retaggio Industries IPO opens today: Price band, GMP, and key details to knowRetaggio Industries' Rs 16 crore SME IPO will be available for subscription from March 27 to April 2 with shares priced at Rs 25 each. The ...
- 5,000 drug manufacturing units may miss Schedule M deadline, industry seeks extensionNearly half of India's 10,000 drug manufacturing units might not meet the 2025 deadline for upgrading to revised Schedule M standards, risk...
- Hyundai IPO opens tomorrow: Can investors ignore these two red flags?Some investors are hesitant about Hyundai's IPO price, considering it expensive at Rs 1,960 per share. This pricing puts Hyundai's estimate...
- Unfazed by manipulation concerns, SME IPOs continue to flourish with sound listingsSME IPOs show resilience post Sebi scrutiny. Mainboard IPOs face valuation challenges. Transparency and careful analysis recommended for SM...
- Decoded: How India makes affordable drugs for developed world, but ‘deadly’ medicines for developing countriesIndia is called the 'pharmacy of the world' because it makes and exports drugs worth millions of dollars to many countries. But recent inci...
- Action taken against pharma cos following reports of deaths, injuries due to their substandard drugs abroad: GovernmentThe Central Drugs Standard Control Organisation in coordination with state authorities initiated action against pharma companies following ...
- Government asks FICCI to close stall selling herbal cigarettes at wellness fairArora also pointed to other violations, including display of cigarettes at the counter and a person promoting cigarettes in the stall with ...
- India’s drug regulator may scrap need to renew licences and approvalsThe government is planning a major overhaul of the country's drug policy, with moves that include scrapping the need to renew manufacturing...
- EIC, USFDA ink pact to share information on import alertsThe pact would "allow EIC (Export Inspection Council) to conduct quick cause analysis in time to support the Indian exporter," the commerce...
- Flies in Ranbaxy's Toansa plant's sample storage room,says FDAOther lapses included usage of un-calibrated and unqualified instruments in laboratory, said the report, which was released two days ago.
- Ranbaxy import ban: USFDA found suspected hair, oil in tabletsUS health regulator made 11 observations citing various violations of current good manufacturing practices (CGMP).
- Amid debt crisis, European construction firms head to QatarFaced with a worsening debt crisis , several major European cos seeking new investment opportunities will be attending the annual Qatar Pro...
Load More
